Class: Chelating agent
- Tablets for oral suspension 125 mg
- Tablets for oral suspension 250 mg
- Tablets for oral suspension 500 mg
Orally active chelating agent that has a high affinity for binding with iron.
Bioavailability is 70%. Median time to T max is approximately 1.5 to 4 h. C max and AUC increase approximately linearly. The bioavailability (AUC) was variably increased when taken with a meal.
Protein binding is approximately 99% and almost exclusively to serum albumin. Vd is approximately 14 L.
Major metabolic pathway is glucuronidation, with subsequent biliary excretion. Deferasirox is deconjugated in the intestine and undergoes enterohepatic recirculation.
Primarily excreted in feces (84%) with minimal renal excretion (8%). Elimination half-life ranges from 8 to 16 h.
Special PopulationsRenal Function Impairment
Minimal excretion (8%) via the kidney.Hepatic Function Impairment
Pharmacokinetics were not influenced by liver transaminase levels up to 5 times the ULN.Elderly
Pharmacokinetics have not been studied in patients 65 yr of age and older.Children
In children younger than 6 yr of age, systemic exposure was approximately 50% lower than in adults.Gender
Cl appears to be moderately lower (17.5%) in women than in men.
Indications and Usage
Treatment of chronic iron overload caused by blood transfusions (transfusional hemosiderosis) in patients 2 yr of age and older.
CrCl less than 40 mL/min or serum creatinine more than 2 times the age-appropriate ULN; poor performance status and high-risk myelodysplastic syndromes or advanced malignancies; platelet counts less than 50 × 10 9 /L; known hypersensitivity to deferasirox.
Dosage and AdministrationAdults and Children 2 yr of age and older Initial dose
PO Start when patient has evidence of chronic iron overload and a serum ferritin consistently more than 1,000 mcg/L. Initial dosage is 20 mg/kg daily.Maintenance Dose
PO Adjust the dose as needed every 3 to 6 mo based on serum ferritin trends. Make dose adjustments in steps of 5 or 10 mg/kg based on patient's response and therapeutic goals. For patients not adequately controlled with doses of 30 mg/kg, doses of up to 40 mg/kg (max dose) may be considered. Consider interrupting therapy if serum ferritin consistently falls below 500 mcg/L.Dosage Adjustment for Renal Function Impairment
Dose reduction, interruption, or discontinuation should be considered for increases in serum creatinine. If there is a progressive increase in serum creatinine beyond the age-appropriate ULN, interrupt deferasirox therapy. Once creatinine has returned to within the normal range, therapy may be restarted at a lower dose followed by gradual dose escalation. For adult patients, reduce the daily dose by 10 mg/kg if serum creatinine increases to more than 33% above the average of the pretreatment measurements at 2 consecutive visits, and if the increase cannot be attributed to other causes. For children, reduce the dose by 10 mg/kg if serum creatinine levels rise above the age-appropriate ULN at 2 consecutive visits.
- Administer once daily on an empty stomach at least 30 min before food, preferably at the same time each day.
- Tablets are for suspension only. Do not chew or swallow whole.
- Calculate dose to the nearest whole tablet.
- Completely disperse tablet by stirring in water, orange juice, or apple juice until a fine suspension is obtained. Disperse doses less than 1 g in 3.5 oz of liquid, and disperse doses of 1 g or more in 7 oz of liquid. Drink suspension immediately.
- Resuspend any residue in a small volume of liquid and swallow.
Store between 59° and 86°F. Protect from moisture.
Drug InteractionsAluminum-containing antacids (eg, aluminum hydroxide)
Deferasirox absorption may be decreased. Avoid coadministration.Anticoagulants (eg, warfarin)
The risk of hemorrhage may be increased as a result of additive side effects. Use with caution. Monitor for signs and symptoms of hemorrhage. If serious bleeding occurs, initiate prompt evaluation and treatment.Bisphosphonates (eg, alendronate), corticosteroids (eg, prednisone), NSAIDs (eg, ibuprofen)
The risk of GI irritation and ulcers may be increased as a result of additive side effects. Use with caution. Monitor for signs and symptoms of GI ulceration. If a serious GI adverse event occurs, initiate prompt evaluation and treatment.Cholestyramine, potent UDP-glucuronosyltransferase (UGT) inducers (eg, phenobarbital, phenytoin, rifampin, ritonavir)
Deferasirox efficacy may be decreased. If coadministration of deferasirox cannot be avoided, consider increasing the initial dose of deferasirox to 30 mg/kg. Monitor serum ferritin concentrations and the patient's clinical response for further dose modification.CYP3A4 substrates (eg, cyclosporine, midazolam, simvastatin)
Concentrations may be reduced by deferasirox, decreasing the effectiveness. Use with caution. Monitor CYP3A4 substrate concentrations and observe the patient for signs of reduced response. Adjust the substrate dose as needed.Hormonal contraceptives
Hormonal contraceptive concentrations may be reduced, decreasing the efficacy. Because hormonal contraceptive failure is possible, consider use of an additional nonhormonal contraceptive.Other iron chelator therapy (eg, deferoxamine)
Do not coadminister because safety has not been established.Paclitaxel
Paclitaxel plasma concentrations may be elevated, increasing the pharmacologic effect and risk of toxicity. Use with caution. Monitor the patient and adjust treatment as needed.Repaglinide
Repaglinide systemic exposure (AUC) and plasma concentrations may be elevated, increasing the pharmacologic effect and risk of adverse reactions. If deferasirox and repaglinide are coadministered, consider decreasing the dose of repaglinide. Carefully monitor blood glucose concentrations for further repaglinide dose modifications.
Anxiety, dizziness, fatigue, sleep disorder (0.1% to 1%).
Rash (11%); pigmentation disorder (0.1% to 1%); leukocytoclastic vasculitis (postmarketing).
Early cataract, hearing loss, maculopathy (0.1% to 1%).
Abdominal pain (28%); nausea (23%); vomiting (21%); diarrhea (20%); cholelithiasis, duodenal ulcers, gastric ulcer (including multiple ulcers), gastritis, GI hemorrhage (0.1% to 1%).
Renal tubulopathy (Fanconi syndrome) (0.1% to 1%); acute renal failure (postmarketing).
Cytopenias, including agranulocytosis, neutropenia, and thrombocytopenia (postmarketing).
Hepatic failure, some with fatal outcome (postmarketing).
Anaphylaxis, angioedema (postmarketing).
Increased creatinine (38%); increased ALT (8%).
Edema, pharyngolaryngeal pain, pyrexia (0.1% to 1%).
WarningsRenal or hepatic failure and/or GI hemorrhage
Deferasirox may cause renal or hepatic impairment (including failure) and/or GI hemorrhage; some reactions have been fatal. These reactions were observed more frequently in patients with advanced age, high-risk myelodysplatic syndromes, underlying renal or hepatic impairment, or platelets less than 50 × 10 9 /L. Deferasirox therapy requires close monitoring.
Measure serum ferritin monthly to assess response to therapy and the possibility of overchelation. Closely monitor proteinuria. Monitor serum ferritin monthly. Monitor serum creatinine and/or CrCl before initiating therapy and monthly thereafter; in patients with underlying renal impairment or risk factors for impairment, monitor creatinine and/or CrCl weekly for the first month and weekly thereafter. Monitor serum transaminases and bilirubin prior to initiation of therapy, every 2 wk during the first month and monthly thereafter. Monitor blood cell counts regularly. Auditory and ophthalmic testing are recommended before the start of treatment and every 12 mo thereafter.
Category C .
Safety and efficacy not established in children younger than 2 yr of age.
Use with caution, usually starting at the low end of the dosage range because of the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant diseases or other drug therapy.
Serious hypersensitivity reactions (eg, anaphylaxis, angioedema) have been reported, with the onset of the reaction occurring in the majority of cases within the first month of treatment.
Agranulocytosis, neutropenia, and thrombocytopenia, including cases with fatal outcomes, have been reported.
Fatal GI hemorrhages, especially in elderly patients who had advanced hematologic malignancies and/or low platelet counts, have been reported.
May occur. For rashes of mild to moderate severity, deferasirox may be continued without dose adjustment because the rash often resolves spontaneously. In severe rash, interrupt therapy and consider reintroduction at a lower dose in combination with a short course of oral steroids.
Auditory disturbances (eg, decreased hearing, high-frequency hearing loss) and ocular disturbances (eg, cataract, elevations in IOP, lens opacities, retinal disorders) have been reported.
Diarrhea, hepatitis, nausea.
- Advise patient to take deferasirox once daily on an empty stomach at least 30 min prior to food, preferably at the same time each day.
- Advise patient not to chew or swallow the tablet whole.
- Instruct patient to completely disperse the tablet in water, orange juice, or apple juice, and to drink the resulting suspension immediately.
- Instruct patient to resuspend any remaining residue in a small volume of liquid and swallow.
- Caution patient to not take deferasirox with aluminum-containing antacids.
- Advise patients to exercise caution when driving or operating machinery if they experience dizziness.
- Advise patients to interrupt treatment if severe skin rashes occur.
- Inform patients about the potential risk of GI ulcers or bleeding when taking deferasirox with drugs such as NSAIDs, corticosteroids, oral bisphosphonates, or anticoagulants.
- Advise patients of the importance of auditory and ophthalmic testing at regular intervals during treatment.
- Advise patients to carefully monitor glucose levels when repaglinide is used concomitantly with deferasirox.
- Advise patients that there have been reports of severe kidney and liver problems and of blood disorders, and that blood tests will be performed at regular intervals to monitor for these severe reactions.
Copyright © 2009 Wolters Kluwer Health.